Policy - onset.to

January 3, 2027

UK petition calls for a legal review of psilocybin access and policy, asking Parliament to consider reform for medical use, research, and reduced criminal penalties

petition.parliament.uk · Jan 3, 2027

Psilocybin Mainstream Policy Research

Today October 5, 2026

Psyence signs a US ibogaine manufacturer, but DEA approvals, import limits, quotas, and clinical filings remain unresolved

behavioralwire.com · Oct 5, 2026 · Editorial Desk

Ibogaine Article Industry Policy Research

Podcast: Oregon abandons psilocybin fee hike as California funds research and DEA again moves to schedule five tryptamines

psychedelicalpha.com · Oct 5, 2026 · Josh Hardman

Psilocybin Podcast Industry Policy Research

Robert Rush challenges the DEA’s evidence and proposed Schedule I classification of five tryptamines

divergentstates.buzzsprout.com · Oct 5, 2026

Podcast Ethics Policy Research

FDA Seeks Public Input on Early-Phase Clinical Trial Design and Safety for Ibogaine Drug Products

fda.gov · Oct 5, 2026

Ibogaine Article Clinical Policy Safety

October 3, 2026

Federal judge calls Flock search unconstitutional as lawmakers introduce a bill to ban license plate readers

techspot.com · Oct 3, 2026 · Daniel Sims

Article Policy Society Technology

October 2, 2026

Tell the FDA What Psychedelic Care Should Look Like: Why Chronic Pain Must Be Included Before the Comment Deadline

psychedelicstoday.com · Oct 2, 2026 · Joe Moore

Psilocybin Ketamine Article Clinical +2

Is HHS too cosy with the psychedelic industry, and is the public being misled about psychedelic risks?

ecstaticintegration.org · Oct 2, 2026 · Jules Evans

LSD Psilocybin Article Industry +2

September 30, 2026

DEA proposes Schedule I status for five tryptamines as Oregon drops psilocybin fee hikes and GAO questions scheduling procedures

psychedelicstoday.com · Sep 30, 2026 · Jack Gorsline

Psilocybin Article Industry Policy Research

September 29, 2026

MAPS opposes the DEA's attempt to place five lesser-known tryptamines into Schedule I under the Controlled Substances Act

maps.org · Sep 29, 2026 · Ismail L. Ali, J.D.

Article Policy Research Safety

September 24, 2026

Psychedelic Churches and the Expanding Legal Landscape of Religious Exemptions Amid Commercialization and Regulatory Scrutiny

yalejreg.com · Sep 24, 2026 · Elizabeth Sepper

Psilocybin Ayahuasca Article Ethics +2

September 23, 2026

DEA proposes Schedule I classification for five synthetic tryptamine psychedelics, threatening research and clinical development

mindmedicinelaw.com · Sep 23, 2026 · The Psychedelic Journal

Article Policy Research Safety

DEA renews effort to place five psychedelic tryptamines in Schedule I as FDA research progress draws criticism from advocates

psychedelicamericas.org · Sep 23, 2026 · PSA Media Team, Jack Gorsline

Article Industry Policy Research

September 22, 2026

FDA hearing, VA psychedelic bill claims, and Alabama's marijuana rescheduling objection shape September 2026 policy briefing

psychedelicstoday.com · Sep 22, 2026 · Jack Gorsline

Psilocybin MDMA Article Industry +2

September 21, 2026

Podcast: Psychedelics in D.C., FDA’s Framework, and New Zealand’s MDMA Prescribers

psychedelicalpha.com · Sep 21, 2026 · Josh Hardman

Ibogaine MDMA Podcast Industry +2

September 18, 2026

Health Canada authorizes Optimi's natural psilocybin depression trial as a US House bill considers 12-year botanical drug exclusivity

psychedelicstoday.com · Sep 18, 2026 · Jack Gorsline

Psilocybin Article Clinical Industry Policy

September 16, 2026

Lynn Watkins Told the FDA About Chronic Pain, Facilitated Touch, and Psychedelic Delivery, Not the Misattributed Reuters Quote

psychedelicstoday.com · Sep 16, 2026 · Joe Moore

Psilocybin Article Clinical Policy Research

Pα+ Psychedelic Bulletin #231 covers Compass’s 52-week psilocybin follow-up, Xylo’s Phase I trial, ibogaine policy, and industry news

psychedelicalpha.com · Sep 16, 2026

Psilocybin Ibogaine Article Industry +2

September 15, 2026

FDA reclassifies NRx's generic ketamine amendment from Major to Minor, setting a November review goal after a vial-cap deficiency

behavioralwire.com · Sep 15, 2026 · Editorial Desk

Ketamine Article Industry Policy Safety

FDA hearing shifts the psychedelic approval debate toward who must deliver treatment and what training, oversight, and safety infrastructure are required

behavioralwire.com · Sep 15, 2026 · Behavioral Wire Staff

Psilocybin Article Clinical Policy Safety

FDA’s Psychedelics Public Hearing Draws Broad Support but No Questions from Federal Panel

psychedelicalpha.com · Sep 15, 2026 · Josh Hardman

Psilocybin Ketamine Article Policy +2

September 14, 2026

Considerations for Potential Future Therapeutic Use of Psychedelic Drugs Public Hearing

youtube.com · Sep 14, 2026 · U.S. Food and Drug Administration

Video Clinical Policy Research

September 12, 2026

VA Secretary Doug Collins discusses fast-tracking psychedelic drug use to help veterans struggling with PTSD

foxnews.com · Sep 12, 2026

Video Clinical Mainstream Policy

September 11, 2026

Psilocybin may prevent chemotherapy nerve pain as LSD, MDMA and psychedelic therapies advance through research and regulation

themicrodose.substack.com · Sep 11, 2026 · Robin Berghaus

LSD Psilocybin Article Clinical +2

Beyond the Foxhole: How Psychedelic Policy Coalitions Are Expanding From Veterans to First Responders Nationwide

psychedelicstoday.com · Sep 11, 2026 · Logan Davidson

Psilocybin Ibogaine Essay Community +2